Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Italian Observational, Multicenter Study in HIV1 -Positive, Virosuppressed Patients Currently in Treatment With Ritonavir-boosted Protease Inhibitors (PI/r) Starting Cobicistat-boosted Darunavir (DRV/c - Rezolsta®): the STart Of REzolsta (ST.O.RE.) Study

NCT02926456 is registered in ClinicalTrials.gov with Janssen-Cilag S.p.A. as lead sponsor.

NCT NCT02926456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02926456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Italian Observational, Multicenter Study in HIV1 -Positive, Virosuppressed Patients Currently in Treatment With Ritonavir-boosted Protease Inhibitors (PI/r) Starting Cobicistat-boosted Darunavir (DRV/c - Rezolsta®): the STart Of REzolsta (ST.O.RE.) Study
Lead sponsor
Janssen-Cilag S.p.A.
Phase
Observational
Overall status
Completed
Start date
July 22, 2016
Completion date
February 14, 2018
Enrollment
337 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus